Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

CHEERS Open Period 1 - All Technical Areas

Active
FA238424S2334Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Air Force Research Laboratory Human Effectiveness Directorate and the United States Air Force School of Aerospace Medicine are soliciting white papers under the Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) Multiple Authority Announcement. This broad agency announcement, solicitation number FA2384-24-S-2334, focuses on defense-related scientific research in human performance and aerospace medicine to support the Department of the Air Force Strategic Vision. The procurement follows a two-step process, starting with the submission of white papers due by September 30, 2027, with technical and cost proposals requested from selected applicants at a later date. The total value of all awards under this solicitation will not exceed 484.73 million dollars, with multiple awards anticipated. The contract incorporates various FAR and DFARS clauses, including strict security requirements for classified information and compliance with military standards for packaging and marking, specifically MIL-STD-129 and MIL-STD-130. Invoicing must be processed through the Web Application for Warranted Funds. Offerors are required to maintain active registration in the System for Award Management and certify their size status and socioeconomic categories. Submissions must be sent electronically to the designated program email and adhere to the formatting guidelines provided in the CHEERS MAA Industry Guide.

General Info

Air Force seeks white papers for human performance research up to $484.73M, due Sept 30, 2027, with strict compliance and registration requirements.

Agency

Department Of Defense → Air Force Research Laboratory

Place of Performance

Not specified

Set-Aside

NONE

Documents

2

FA2384-24-S-2334 Amendment 01 - List of Provisions and Clauses

PDF, High priority: read this firstamendment
High

FA2384-24-S-2334 CHEERS Open Period Solicitation 1 - All Technical Areas

PDF, High priority: read this firstbaa
High

AI Contract Breakdown

Uniform Contract Format

Sign up to view the full breakdown with detailed analysis of each section.

Timeline

PhaseSolicitation
Posted

Solicitation

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Air Force Research Laboratory
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Defense → Air Force Research Laboratory
Office AddressUSA
Contacts

Full Description

Show more

The Air Force Research Laboratory, Human Effectiveness Directorate (RH) and the United States Air Force School of Aerospace Medicine (USAFSAM), is soliciting white papers (and potentially later technical and cost proposals) on the research located in the Statements of Objectives attached to the Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) Multiple Authority Announcement (MAA) Opportunity FA2384-24-S-2233.


List of Attachments:


1. "Open Period Solicitation 1_BAA Amend 01"


2. "Attachment 1 - List of Provisions and Clauses (BAA)"



Related Notice: Multiple Authority Announcement (MAA) FA238424S2233, "Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS)"

Note: You MUST refer to the related notice identified above in order to obtain all additional attachments referenced herein (e.g. CHEERS Industry Guide, Statements of Objectives (SOO), and S&T Protection Appendices)

Similar Contracts

Same NAICS industry code

NAICS: 541715
New
Federal
U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) Organic Industrial Base (OIB) Modernization Commercial Solutions Opening (CSO)
Solicitation # W911PT26SC001
The U.S. Army Contracting Command – Watervliet Arsenal (ACC-WVA) has issued solicitation W911PT26SC001, a Commercial Solutions Opening (CSO) authorized under the National Defense Authorization Act for Fiscal Year 2026 and DFARS Subpart 212.70. This competitive solicitation is open until September 30, 2027, and is designed to acquire innovative commercial products, technologies, and services to modernize the Army's Organic Industrial Base. The scope focuses on integrating manufacturing resources, linking legacy analogue systems with digital systems, and expanding modeling and simulation to enhance the delivery of materiel solutions. The CSO targets both traditional and non-traditional business entities, including small businesses and foreign-owned firms, provided they maintain an active System for Award Management (SAM) profile and a Unique Entity ID. The acquisition process follows a multi-phased approach consisting of a written solution brief, an optional presentation or pitch, and a final Request for Commercial Solution Proposal (CSP). Evaluation is based on responsiveness, technical merit, uniqueness, and price reasonableness. Successful responses may result in fixed-price contracts awarded under FAR Part 12 Commercial Item Procedures. Current Areas of Interest (AoIs) include advanced cannon technology, electrical infrastructure improvements at Building 120, chromium facility conversion, automated manufacturing for minor components, automated cooling tower treatments, advanced CNC vertical turning lathes, and advanced tooling for radial forging. Performance is primarily located at Watervliet Arsenal and Benet Laboratories, with a general period of performance not to exceed 12 months unless otherwise specified.
W6QK Acc Wva

POSTED

about 5 hours ago

DEADLINE

in 12 months
View Details
NAICS: 541715
New
Federal
L-PBF Development of ODS Alloys for Recording Methane/Oxygen Combustion Properties
Solicitation # 80NSSC27946801Q
The NASA Shared Services Center is seeking capability statements for a project focused on the laser powder bed fusion (L-PBF) development of oxide dispersion strengthened (ODS) and burn-resistant nickel-based alloys, including GRX-810, GRX-810+, and GRX-900. The scope of work involves advanced process development and parameter optimization using an EOS M280 system to achieve a relative density of 99.9 percent or higher. Key requirements include the production of test coupons and representative components, the supply of at least 600 kg of GRX-810 powder, and strict adherence to NASA-STD-6030 for mechanical validation. All deliverables must be shipped to the Marshall Space Flight Center in Huntsville, Alabama. This procurement is being conducted as a commercial items or services acquisition under FAR Part 12, with NAICS code 541715. NASA intends to issue a sole source contract to North American Manufacturing Pros LLC under FAR 12.102(a); however, the agency is requesting capability statements from other interested organizations to determine if the procurement should be conducted on a competitive basis. Interested parties must submit their qualifications to the primary point of contact, Cara Craft, by October 22, 2026. The contract requires rigorous documentation, including real-time reporting of anomalies and full powder traceability certifications covering chemical composition and particle morphology.
NASA Shared Services Center

POSTED

1 day ago

DEADLINE

in 2 days
View Details
NAICS: 541715
New
Federal
Prototype development for Battlefield Wound Infection Prevention and Treatment (BWI P&T) Barrier Combination
Solicitation # HT9427-26-R-E020
The Defense Health Agency Contracting Activity is seeking proposals for the development of a Battlefield Wound Infection Prevention and Treatment Barrier Combination prototype. This product must integrate a physical wound barrier with antimicrobial and antifungal properties to prevent systemic infections in combat scenarios. The project aims to advance the technology to a Technology Readiness Level of 7 or 8, requiring the development of a working prototype, the execution of human clinical trials, and the successful submission for FDA approval or clearance. The final product must be individual, compact, waterproof, and maintain sterilization, with a preference for packaging that allows one-handed opening in low-light environments. This effort is being conducted under the prototype Other Transaction Authority 10 U.S.C. 4022, meaning it does not follow standard FAR-based procurement. To be eligible, offerors must be nontraditional defense contractors, small businesses, or provide significant cost-sharing. The estimated period of performance is 48 months, divided into three objectives: prototype demonstration, clinical studies and regulatory submissions, and final FDA clearance. Proposals will be evaluated based on technical capability, management capability, and cost, with payments processed electronically via Wide Area Workflow. All clinical research must comply with Good Laboratory, Manufacturing, and Clinical Practices, and be approved by relevant Institutional Review Boards and the USAMRDC Office of Human and Animal Research Oversight.
Defense Health Agency

POSTED

1 day ago

DEADLINE

in 17 days
View Details
NAICS: 541715
New
Federal
Request for Information – Prophylactic Platform for Medical Countermeasures
Solicitation # W911SR27SPPFC
The Department of Defense, through the Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense (PME CBRND) and the Accelerated Defense Pharmaceuticals (ADP) program, is issuing a Request for Information (RFI) under solicitation W911SR27SPPFC. The objective is to identify capable companies that can advance the development of prophylactic medical countermeasures (MCMs) using existing platform technologies. The program focuses on progressing these countermeasures through Phase I or Phase II clinical trials, with a goal of enabling interim fielding via Expanded Access Protocols or pre-Emergency Use Authorization. The anticipated period of performance is up to four years, with work primarily conducted at the contractor's facilities. Interested respondents must provide a comprehensive capability description, including technical approach, regulatory status with the FDA, cGMP manufacturing capabilities, and a development roadmap with rough order of magnitude cost estimates. Evaluation criteria for future selections will emphasize manufacturing process capability, product safety and efficacy, past FDA experience, and the plug-and-play nature of the platform across various pathogens. Submissions must be delivered as a single searchable PDF, featuring a specific cover page and a core capability description not exceeding four pages. All non-clinical and clinical data must be SEND and CDISC compliant, and manufacturing must adhere to cGMP standards to support an Investigational New Drug application through a Biologics License Application.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

in 29 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS